US FDA approves updated COVID shots ahead of fall and winter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Brookline Capital Markets Reiterates Buy Rating on Moderna (MRNA)
August 23, 2024 7:50 AM EDTBrookline Capital Markets analyst Leah Rush Cann reiterated a Buy rating and $310.00 price target on Moderna (NASDAQ: MRNA).
The analyst comments "Conclusions Todays announcement that FDA has approved Modernas new formulation for its COVID-19 vaccine (2024-2025 formulation) targeting the KP.2 variant of SARS-CoV-2, the variant based on guidance from the FDA. This approval follows a... More
Moderna (MRNA) Receives European Commission Approval for RSV Vaccine mRESVIA(R)
August 23, 2024 7:03 AM EDTModerna, Inc. (NASDAQ: MRNA) today announced that the European Commission (EC) has granted marketing authorization for mRESVIA® (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The marketing authorization follows the Positive Opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The authorization is valid in all 27 EU member states, as well as Iceland, Liechtenstein and Norway.
"The... More
